Dupilumab and House Dust Mite Immunotherapy in Patients with Atopic Dermatitis: A Preliminary Study
Background: Severe atopic dermatitis (AD) is a complex disease requiring systemic treatment. This study aimed to assess the effectiveness of combined therapy consisting of dupilumab and sublingual dust mite allergen immunotherapy (SLIT-HDM) in patients with severe AD and HDM allergies. Methods: Pati...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-09-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/12/9/1046 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850259208553889792 |
|---|---|
| author | Agnieszka Bogacz-Piaseczyńska Andrzej Bożek Magdalena Krupka-Olek Aleksandra Kawczyk-Krupka Jolanta Zalejska-Fiolka Giorgio Walter Canonica |
| author_facet | Agnieszka Bogacz-Piaseczyńska Andrzej Bożek Magdalena Krupka-Olek Aleksandra Kawczyk-Krupka Jolanta Zalejska-Fiolka Giorgio Walter Canonica |
| author_sort | Agnieszka Bogacz-Piaseczyńska |
| collection | DOAJ |
| description | Background: Severe atopic dermatitis (AD) is a complex disease requiring systemic treatment. This study aimed to assess the effectiveness of combined therapy consisting of dupilumab and sublingual dust mite allergen immunotherapy (SLIT-HDM) in patients with severe AD and HDM allergies. Methods: Patients diagnosed with severe AD were included in this randomised, placebo-controlled, double-blind 12-month trial; they received SLIT for HDMs and/or dupilumab for 12 months and were compared with patients on cyclosporine. The primary outcomes for the treatment arms were changes in the Eczema Area and Severity Index (EASI), body surface area (%BSA), and Investigator Global Assessment (IsGA) over 12 months. The secondary outcomes were the proportion of patients who achieved IsGA success and reduced medication scores. Results: Significant improvements were observed in all analysed groups after 12 months of therapy based on the EASI, %BSA, and IsGA. However, the most substantial changes were observed in the groups treated with dupilumab or a combination of SLIT-HDM and dupilumab. Additionally, the proportion of patients who achieved an IsGA reduction was significantly greater in the group receiving combination therapy than in the other groups (9/14 [64% of the group receiving SLIT-HDM] vs. 11/14 [73% of the group receiving dupilumab] vs. 15/17 [88% of the group receiving dupilumab and SLIT-HDM] vs. 7/13 [53% of the group receiving cyclosporine]) (<i>p</i> < 0.05). Conclusions: In patients with severe AD and HDM allergies, combination treatment with dupilumab and allergen immunotherapy for HDMs may increase the therapeutic benefit over treatment with these methods separately. |
| format | Article |
| id | doaj-art-b5efcd04b5c04a19abe47dc19e70e744 |
| institution | OA Journals |
| issn | 2076-393X |
| language | English |
| publishDate | 2024-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj-art-b5efcd04b5c04a19abe47dc19e70e7442025-08-20T01:55:57ZengMDPI AGVaccines2076-393X2024-09-01129104610.3390/vaccines12091046Dupilumab and House Dust Mite Immunotherapy in Patients with Atopic Dermatitis: A Preliminary StudyAgnieszka Bogacz-Piaseczyńska0Andrzej Bożek1Magdalena Krupka-Olek2Aleksandra Kawczyk-Krupka3Jolanta Zalejska-Fiolka4Giorgio Walter Canonica5Clinical Department of Internal Diseases, Dermatology and Allergology, Medical University of Silesia, 40-055 Katowice, PolandClinical Department of Internal Diseases, Dermatology and Allergology, Medical University of Silesia, 40-055 Katowice, PolandClinical Department of Internal Diseases, Dermatology and Allergology, Medical University of Silesia, 40-055 Katowice, PolandDepartment of Internal Medicine, Angiology and Physical Medicine, Center for Laser Diagnostics and Therapy, Medical University of Silesia, Batorego 15 Street, 41-902 Bytom, PolandDepartment of Biochemistry, Faculty of Medical Science, Zabrze Medical University of Silesia, 40-055 Katowice, PolandHead Personalized Medicine Asthma & Allergy Clinic-Humanitas Research Hospital, Humanitas University, 20089 Milano, ItalyBackground: Severe atopic dermatitis (AD) is a complex disease requiring systemic treatment. This study aimed to assess the effectiveness of combined therapy consisting of dupilumab and sublingual dust mite allergen immunotherapy (SLIT-HDM) in patients with severe AD and HDM allergies. Methods: Patients diagnosed with severe AD were included in this randomised, placebo-controlled, double-blind 12-month trial; they received SLIT for HDMs and/or dupilumab for 12 months and were compared with patients on cyclosporine. The primary outcomes for the treatment arms were changes in the Eczema Area and Severity Index (EASI), body surface area (%BSA), and Investigator Global Assessment (IsGA) over 12 months. The secondary outcomes were the proportion of patients who achieved IsGA success and reduced medication scores. Results: Significant improvements were observed in all analysed groups after 12 months of therapy based on the EASI, %BSA, and IsGA. However, the most substantial changes were observed in the groups treated with dupilumab or a combination of SLIT-HDM and dupilumab. Additionally, the proportion of patients who achieved an IsGA reduction was significantly greater in the group receiving combination therapy than in the other groups (9/14 [64% of the group receiving SLIT-HDM] vs. 11/14 [73% of the group receiving dupilumab] vs. 15/17 [88% of the group receiving dupilumab and SLIT-HDM] vs. 7/13 [53% of the group receiving cyclosporine]) (<i>p</i> < 0.05). Conclusions: In patients with severe AD and HDM allergies, combination treatment with dupilumab and allergen immunotherapy for HDMs may increase the therapeutic benefit over treatment with these methods separately.https://www.mdpi.com/2076-393X/12/9/1046atopic dermatitisimmunotherapydupilumabhouse dust mites |
| spellingShingle | Agnieszka Bogacz-Piaseczyńska Andrzej Bożek Magdalena Krupka-Olek Aleksandra Kawczyk-Krupka Jolanta Zalejska-Fiolka Giorgio Walter Canonica Dupilumab and House Dust Mite Immunotherapy in Patients with Atopic Dermatitis: A Preliminary Study Vaccines atopic dermatitis immunotherapy dupilumab house dust mites |
| title | Dupilumab and House Dust Mite Immunotherapy in Patients with Atopic Dermatitis: A Preliminary Study |
| title_full | Dupilumab and House Dust Mite Immunotherapy in Patients with Atopic Dermatitis: A Preliminary Study |
| title_fullStr | Dupilumab and House Dust Mite Immunotherapy in Patients with Atopic Dermatitis: A Preliminary Study |
| title_full_unstemmed | Dupilumab and House Dust Mite Immunotherapy in Patients with Atopic Dermatitis: A Preliminary Study |
| title_short | Dupilumab and House Dust Mite Immunotherapy in Patients with Atopic Dermatitis: A Preliminary Study |
| title_sort | dupilumab and house dust mite immunotherapy in patients with atopic dermatitis a preliminary study |
| topic | atopic dermatitis immunotherapy dupilumab house dust mites |
| url | https://www.mdpi.com/2076-393X/12/9/1046 |
| work_keys_str_mv | AT agnieszkabogaczpiaseczynska dupilumabandhousedustmiteimmunotherapyinpatientswithatopicdermatitisapreliminarystudy AT andrzejbozek dupilumabandhousedustmiteimmunotherapyinpatientswithatopicdermatitisapreliminarystudy AT magdalenakrupkaolek dupilumabandhousedustmiteimmunotherapyinpatientswithatopicdermatitisapreliminarystudy AT aleksandrakawczykkrupka dupilumabandhousedustmiteimmunotherapyinpatientswithatopicdermatitisapreliminarystudy AT jolantazalejskafiolka dupilumabandhousedustmiteimmunotherapyinpatientswithatopicdermatitisapreliminarystudy AT giorgiowaltercanonica dupilumabandhousedustmiteimmunotherapyinpatientswithatopicdermatitisapreliminarystudy |